Aims: Automation of downstream analysis may offer many potential benefits to routine histopathology. One area of interest for automation is in the scoring of multiple immunohistochemical markers in order to predict the patient's response to targeted therapies. Automated serial slide analysis of this kind requires robust registration to identify common tissue regions across sections. We present an automated method for co-localised scoring of Estrogen Receptor and Progesterone Receptor (ER/PR) in breast cancer core biopsies using whole slide images. Methods and Results: Regions of tumour in a series of fifty consecutive breast core biopsies were identified by annotation on H&E whole slide images. Sequentially cut immunohistochemica...
Introduction Manual interpretation of immunohistochemistry (IHC) is a subjective, time-consuming and...
The benefit of quantifying estrogen receptor (ER) and progesterone receptor (PR) expression in breas...
Her-2/neu is overexpressed in 20-30% of breast cancer patients and is associated with a more aggress...
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individu...
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individu...
The identification and classification of tissue abnormalities for the purpose of disease diagnosis h...
BackgroundTissue microarrays (TMAs) have become a valuable resource for biomarker expression in tran...
INTRODUCTION: Manual interpretation of immunohistochemistry (IHC) is a subjective, time-consuming an...
Background: The Visiopharm automated estrogen receptor (ER) digital imaging analysis (DIA) algorithm...
The ACROBAT challenge aims to advance the development of whole-slide-image (WSI) registration algori...
The ACROBAT challenge aims to advance the development of whole-slide-image (WSI) registration algori...
Purpose: A woman should be able to trust that the steroid receptor status of her cancer is reported ...
BACKGROUND: High-throughput evaluation of tissue biomarkers in oncology has been greatly accelerated...
Aims: To compare the assessment of steroid hormone receptor immunohistochemistry by eye and by compu...
Introduction: A significant barrier to medical diagnostics in low-resource environments is the lack ...
Introduction Manual interpretation of immunohistochemistry (IHC) is a subjective, time-consuming and...
The benefit of quantifying estrogen receptor (ER) and progesterone receptor (PR) expression in breas...
Her-2/neu is overexpressed in 20-30% of breast cancer patients and is associated with a more aggress...
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individu...
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individu...
The identification and classification of tissue abnormalities for the purpose of disease diagnosis h...
BackgroundTissue microarrays (TMAs) have become a valuable resource for biomarker expression in tran...
INTRODUCTION: Manual interpretation of immunohistochemistry (IHC) is a subjective, time-consuming an...
Background: The Visiopharm automated estrogen receptor (ER) digital imaging analysis (DIA) algorithm...
The ACROBAT challenge aims to advance the development of whole-slide-image (WSI) registration algori...
The ACROBAT challenge aims to advance the development of whole-slide-image (WSI) registration algori...
Purpose: A woman should be able to trust that the steroid receptor status of her cancer is reported ...
BACKGROUND: High-throughput evaluation of tissue biomarkers in oncology has been greatly accelerated...
Aims: To compare the assessment of steroid hormone receptor immunohistochemistry by eye and by compu...
Introduction: A significant barrier to medical diagnostics in low-resource environments is the lack ...
Introduction Manual interpretation of immunohistochemistry (IHC) is a subjective, time-consuming and...
The benefit of quantifying estrogen receptor (ER) and progesterone receptor (PR) expression in breas...
Her-2/neu is overexpressed in 20-30% of breast cancer patients and is associated with a more aggress...